Last reviewed · How we verify
paliperidone clozapine
Paliperidone and clozapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms.
Paliperidone and clozapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms. Used for Schizophrenia, Schizoaffective disorder, Bipolar disorder (acute agitation).
At a glance
| Generic name | paliperidone clozapine |
|---|---|
| Sponsor | Universidad Nacional de Rosario |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Both agents are second-generation antipsychotics that antagonize dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis. They also block serotonin 5-HT2A receptors, which may enhance dopamine release in the prefrontal cortex and improve negative and cognitive symptoms. Clozapine has additional activity at muscarinic and histamine receptors, contributing to its unique clinical profile.
Approved indications
- Schizophrenia
- Schizoaffective disorder
- Bipolar disorder (acute agitation)
Common side effects
- Extrapyramidal symptoms (akathisia, dystonia, parkinsonism)
- Weight gain
- Metabolic syndrome (hyperglycemia, dyslipidemia)
- Sedation
- Orthostatic hypotension
- Agranulocytosis (clozapine-specific)
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
- An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications (PHASE4)
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paliperidone clozapine CI brief — competitive landscape report
- paliperidone clozapine updates RSS · CI watch RSS
- Universidad Nacional de Rosario portfolio CI